I think that if they conclude their reviews in a shorter period, the total time between the drug's coming on the market and the drug's being listed in our program would be reduced.
As I said, we are trying to reduce the amount of time that we spend looking at our particular population and seeing if it is apropos or if there are some differences. Very minor changes are made between the recommendations in CDR and what we do in terms of listing. We build on after they approve, so if they reduce their amount of time, the total time will go down.